| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 28th December 2020 | James V Caruso | 37,037 | Open or private purchase | $1.35 | $49,999.95 |
| 28th December 2020 | Jarrod Longcor | 29,630 | Open or private purchase | $1.35 | $40,000.50 |
| 28th December 2020 | Dov Elefant | 7,407 | Open or private purchase | $1.35 | $9,999.45 |
| 16th December 2020 | Stephen A Hill | 7,500 | Exercise of derivative | $0.00 | |
| 5th June 2020 | Dov Elefant | 4,348 | Open or private purchase | $1.15 | $4,978.46 |
| 5th June 2020 | James V Caruso | 21,740 | Open or private purchase | $1.15 | $24,892.30 |
| 5th June 2020 | Jarrod Longcor | 65,218 | Open or private purchase | $1.15 | $74,674.61 |
| 4th June 2020 | Stephen A Hill | 18,000 | Open or private purchase | $1.08 | $19,438.20 |
| 3rd February 2020 | Jarrod Longcor | 40,000 | Grant/award etc. | $2.71 | $108,400.00 |
| 3rd February 2020 | James V Caruso | 100,000 | Grant/award etc. | $2.71 | $271,000.00 |
Cellectar Bio Sciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; and CLR 125, which intends to treat micro metastatic disease.
Ticker: CLRB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1279704
Employees: 8
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
